Jp Solar Vasconcelos

Gi Med Onc @bccancer, Clin Asst Prof @UBCDoM. Music, Literature, Pet, and Travel ! Tweets are my own. Ret. ≠ Endors.

[Prof. Feynman @ProfFeynman]

Knowledge grows when you ask stupid questions. Stupidity grows when you don't ask anything.

[Arndt Vogel @ArndtVogel]

Phase III CR-SEQUENCE trial of FOLFOX+pani followed by FOLFIRI+beva (SEQ1) versus FOLFOX + beva followed by FOLFIRI + pani (SEQ2) in RAS WT, left-sided mCRC
#ASCO26
👉no difference in 36mo PFS rate
👉higher ORR with pain
🧐ctDNA and molecular analysis awaited
@myesmo @ASCO

[Personalis, Inc. @PersonalisInc]

#ASCO26 is off to a great start!

Our team is on the ground from May 30 to June 1 at booth # 31141. Stop by and say hello!

We have impactful data being presented this weekend. Pictured below: poster presentation with Joao Paulo Solar Vasconcelos, MD, highlighting molecular residual disease (MRD) detection using an ultrasensitive assay in a prospective colorectal cancer cohort.

Connect with us at ASCO: https://t.co/oNoSimoBDW.

#PrecisionOncology #PrecisionMedicine #ClinicalOncology #CancerResearch #Oncology #MRD #ctDNA #ColorectalCancer

[Jp Solar Vasconcelos @jaypsv]

This was cool!

[Dana-Farber @DanaFarber]

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.

In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.

While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.

As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Congratulations to the researchers and patients who made this important progress possible. 👏👏👏

Video Courtesy: @asco

[Thor Halfdanarson @OncoThor]

A few helpful EMPD references:

https://t.co/pfcYQOClUq

https://t.co/YiP1BlZAa9

[Daily Hive Vancouver @DailyHiveVan]

Terry Fox International Airport? Vancouver mayoral candidate proposes YVR renaming ✈️
https://t.co/cIe2T8M1v9

[Dr. Nina Niu Sanford @NiuSanford]

One of most interesting rectal ca studies at #ASCO26

P3 RCT in pMMR LARC: Node-sparing short-course RT + CAPOX + tislelizumab doubled pCR v conventional SCRT + CAPOX (61 v 29%)

Hypothesis = sparing elective node RT preserves antitumor immunity & improves PD1 response @OncoAlert

[Eric Topol @EricTopol]

What's the right amount of time for resistance training?
A new study supports 90-120 minutes/week across multiple outcomes, which plateaus beyond that for lack of additional benefit
From 30-year follow-up of ~150,000 participants
https://t.co/mUy9o4HkbH

[Kenneth Chan @iamkennethchan]

10 days to go! ⚽ #FIFAWorldCup #WeAre26 #WeAreVancouver

[Thor Halfdanarson @OncoThor]

Non-ASCO oncology news...

The randomized, noncomparative OCLURANDOM trial of Lu-177 DOTATATE vs. sunitinib is now out. As can be seen, the primary endpoint, PFS at 12 months, was 81% vs. 42% with sunitinib, the control arm. The ORR was 63% in the patients receiving PRRT, higher than seen in other studies and the ORR in the patients receiving sunitinib was 30%, much higher than the 9% seen in the NEJM 2011 trial.

This is a valuable addition to the literature but the trial design, randomized but noncomparative, needs to be kept in mind when comparing the arms.

https://t.co/73ufB50U7C

[Allan Pereira, MD, PhD @DrAllanPereira]

#ASCO2026 - Advanced Gastric cancer
Abstract 4007 - Adding oral EP4 antagonist ONO-4578 to chemo + IO in Stage IV gastric cancer.

- Median PFS was significantly longer with ONO-4578 vs placebo
9.0 vs 6.9 months; HR 0.67; 90% CI 0.48–0.92; P=0.040.

- Median OS favored ONO-4578 (not reached vs 12.7 months; HR 0.60; 95% CI 0.37–0.96).

- ORR was higher in the ONO-4578 group (62.0% vs 48.7%). Serious TEAEs occurred in 53.7% vs 42.7%.

IMPORTANT: Results were better for PD-L1 positive tumors.

This Phase II RCT shows that adding the EP4 antagonist ONO-4578 to standard nivo + chemo improves PFS and trends toward OS benefit in 1L HER2-negative gastric/GEJ cancer.

Although OS data are immature and this is a Phase II trial, this is a first demonstration that PGE2-EP4 pathway inhibition can enhance immunotherapy efficacy in this setting - warranting Phase III confirmation.

#GIonc #StomachCancer
@MoffittNews

[Allan Pereira, MD, PhD @DrAllanPereira]

ASCO 2026 - HCC

🧵 Two important HCC abstracts presented today at #ASCO26 add to a rapidly changing landscape:

🔹 Abstract 4001: camrelizumab + rivoceranib + TACE
🔹 LBA4000: EMERALD-3 - STRIDE ± lenvatinib + TACE

TACE alone may no longer be the whole story.

#HCC #LiverCancer
#MoffittASCO26
@MoffittNews

[Daily Hive Vancouver @DailyHiveVan]

B.C. university named to top 1% of best universities in the world 🎓
https://t.co/4jTfSInCbT

[Allan Pereira, MD, PhD @DrAllanPereira]

🚨 Potentially practice-changing results in advanced ESCC:

In a phase III randomized trial, izalontamab brengitecan (iza-bren) significantly improved both PFS and OS compared with chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) who had progressed after first-line platinum-based chemotherapy plus a PD-1/PD-L1 inhibitor.

📈 Median OS: 9.8 vs 7.2 months
HR 0.64 (95% CI, 0.49–0.83); p=0.0004
📈 Median PFS by BICR: 4.2 vs 2.0 months
HR 0.50 (95% CI, 0.40–0.63); p<0.0001

📈 ORR by BICR: 35.3% vs 13.1%
This is a meaningful improvement in a setting with limited effective treatment options.

#ASCO26 #ESCC #EsophagealCancer #GIOnc #ADC #PrecisionOncology @MoffittNews @ASCO

What is iza-bren? 🔬
👇👇👇

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

#ASCO26 @ASCO
FIGHT-302 @GIcancerDoc
1L Pemigatinib vs gem/cis in FGFR2-rearranged advanced cholangiocarcinoma
Closed early d/t change in 1L SOC, n=167 (4563 screened, <4% positivity rate)
- ORR 47% vs 15%
- PFS 8.3m vs 6.8m
- no diff in OS with 50% crossover (mOS 24.4m vs 25m)
Kudos for this effort 👏
Simultaneous @JCO_ASCO publication
@OncoAlert #BTCsm

[NonsparseOncologist @5_utr]

The precision oncology hype machine just found its new weapon to sell a paradigm. CROWN 7yr lorlatinib. 55% progression-free. Median PFS not reached. Proof the paradigm works. Except it isn’t. Let’s go. 🧵

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

#ASCO26 @ASCO
Daraxonrasib in pretreated PDAC RASolute302 #Plenary

So deserving of the standing O 👏 👏 👏

Excellent &amp; passionate discussion by Dr. Jennifer Knox with a Call to Action…and, in the words of Dr. Brian Wolpin, a Call to Science 💜
#TimeIsNow

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

#ASCO26 @ASCO
Cost-utility analysis of #CHALLENGE trial of structured #exercise (SEP) after ACT for stage 2-3 colon cancer @CDNCancerTrials 🇨🇦
📌SEP improves DFS & OS
➡️ SEP is less costly & more effective ‘Win-Win’ ✅
‼️We need to implement SEP into routine care 💪 #NoExcuses
@JCO_AS@JCO_ASCO
🔗 https://t.co/Anfp1cxnHi

[Eric Topol @EricTopol]

There hasn't previously been a treatment vs pancreatic cancer this successful. Striking improved (a > doubling) survival results @NEJM and @ASCO today with daraxonrasib, which also became available via an FDA approved early access program and began shipping to physicians this week @RevMedicines
https://t.co/e04jqJMPw0

[Arndt Vogel @ArndtVogel]

Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial.
#ASCO26
👉exercise improves DFS and OS
👉Despite upfront costs, overall cost effective
🧐provides economic evidence for clinical implantation
@myesmo @ASCO